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Abstract
MicroRNAs are post-transcriptional regulators of gene expression that are differentially reg-
ulated during development and in inflammatory diseases. A role for miRNAs in allergic
asthma is emerging and further investigation is required to determine whether they may
serve as potential therapeutic targets. We profiled miRNA expression in murine lungs from
an ovalbumin-induced allergic airways disease model, and compared expression to ani-
mals receiving dexamethasone treatment and non-allergic controls. Our analysis identified
29 miRNAs that were significantly altered during allergic inflammation. Target prediction
analysis revealed novel genes with altered expression in allergic airways disease and sug-
gests synergistic miRNA regulation of target mRNAs. To assess the impacts of one induced
miRNA on pathology, we targeted miR-155-5p using a specific antagomir. Antagomir
administration successfully reduced miR-155-5p expression with high specificity, but failed
to alter the disease phenotype. Interestingly, further investigation revealed that antagomir
delivery has variable efficacy across different immune cell types, effectively targeting mye-
loid cell populations, but exhibiting poor uptake in lymphocytes. Our findings demonstrate
that antagomir-based targeting of miRNA function in the lung is highly specific, but high-
lights cell-specificity as a key limitation to be considered for antagomir-based strategies as
therapeutics.
Introduction
Allergic asthma is characterized by immune hypersensitivity to allergens [1]. The mechanisms
that lead to hypersensitivity are complex and include the activation of endothelial and immune
cells, immune cell recruitment and changes in gene expression [1]. Despite our knowledge of
factors influencing disease pathogenesis, the available treatments for asthma and allergic
inflammation remain insufficient to adequately control disease [2]. As such, novel therapeutic
strategies are required for the effective treatment of asthma and allergic inflammation.
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MicroRNAs (miRNAs) are conserved single-stranded RNAmolecules (around 22 nucleo-
tides in length) that regulate gene expression by targeting the 3’UTR of mRNA transcripts [3].
MiRNA targeting inhibits translation and destabilizes target mRNAs, resulting in reduced pro-
tein production. MiRNAs play important roles in a variety of biological processes, including
apoptosis, cancer, development and inflammation [4–6]. MiRNA inhibitors are emerging as
effective therapeutics in a range of diseases, including cancer, hepatitis and metabolic disorders
[7, 8]. MiR-122, in particular, is a promising target for the treatment of hepatitis C, with
human clinical trials currently under way [8].
To date, few studies have investigated the role of miRNAs in asthma and murine models of
allergic airways disease (AAD). Several recent human studies provide evidence that miRNAs
may be involved in asthmatic disease [9–11]. In mouse models of AAD, important functions for
let-7, miR-21, miR-126, miR-145 and miR-155 have been demonstrated in disease pathogenesis
[12–19]. MiR-21 expression was increased in several models of AAD and mir-21 deficient mice
have reduced Th2 responses and decreased eosinophilia in an ovalbumin (OVA)-induced model
of AAD [12, 13]. Our group identified upregulation of miR-126 in a house dust mite (HDM)-
induced AADmodel [16, 20]. Localised inhibition of miR-126 in the lung with an antagomir
(antisense miRNA inhibitor) significantly reduced hallmark features of AAD [16]. Our group
also observed that miRNAs let-7b, miR-21 and miR-145 were upregulated in a HDM-induced
model of AAD [17]. While antagomir administration could specifically reduce the levels of each
individual miRNA, inhibition of let-7b andmiR-21 had no significant effect on disease pathogen-
esis [17]. However, blockade of miR-145 did markedly reduce hallmark features of disease [17].
Mir-155-/- mice which lack pri-mir-155 and mature miRNAs, miR-155-5p and miR-155-3p, also
have decreased lung inflammation in models of AAD (18, 19). These findings clearly demon-
strate that individual miRNAs are altered and play functional roles in AAD.
In the present study, we performed miRNA array experiments to reveal altered miRNA
expression (of 29 miRNAs) in an acute, steroid-sensitive, OVA-driven murine model of AAD.
Bioinformatics analysis predicted novel mRNA targets that could be synergistically regulated
by the induced miRNAs, which we confirmed at the mRNA level by quantitative PCR (qPCR).
In vivo targeting of one induced miRNA (mmu-miR-155-5p; referred to as miR-155-5p) with a
specific antagomir successfully reduced miR-155-5p levels, but failed to alter disease pathogen-
esis. Further analysis revealed differing efficacy of antagomir-mediated targeting across differ-
ent immune cell types both in vitro and in vivo. Specifically, antagomir uptake was highly
efficient in myeloid cell populations, but was ineffective at targeting T lymphocytes. Our find-
ings clearly demonstrate altered miRNA gene expression and revealed novel changes in gene
expression during AAD. Importantly, we also demonstrate variable cell targeting as a key limi-
tation of antagomir-based strategies, which must be considered when interpreting findings
from antagomir studies and when designing therapeutic interventions.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with the requirements of the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes. The protocol was specifically
approved by the Animal Care and Ethics Committee (ACEC) of the University of Newcastle
(Permit numbers #1060 and #A-2010-148).
Mice and animal welfare
Specific pathogen-free (SPF) BALB/c mice (8–12 weeks old) were obtained from the University
of Newcastle’s SPF facility and housed in individually ventilated cages in approved
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containment facilities within the Bioresources Facility, Hunter Medical Research Institute
(Newcastle, Australia). Mice were provided with water and food ad libitum and acclimatised
for one week prior to experimentation. All efforts were made to minimize suffering in treated
animals. All treated animals were monitored daily as part of the approved protocol for weight
loss and clinical score. Clinical scores were defined as: 0 = no clinical signs, 1 = rough coat,
2 = rough coat, less reactive, passive during handling. Intervention points by euthanasia were
set as weight loss of over 20% body weight or reaching a clinical score of 2. There were no ani-
mal deaths or interventions required as a result of our protocol. All mice were euthanised by
pentobarbital overdose (Virbac, Australia).
Murine model of allergic airways disease
AAD was induced through sensitisation and inhalational challenges as previously described
[21]. Briefly, mice were systemically sensitised via i.p. injection of 50 μg chicken egg OVA
(Grade V,98% pure, Sigma, Australia) complexed with 1 mg Alhydrogel (Sigma, Australia)
in saline (day 0). Non-sensitized control mice were injected with 1 mg Alhydrogel in saline. On
days 12, 13, 14 and 15, all mice were challenged (i.n.) with 10 μg of OVA in saline. Endpoints
were performed 24 hours after the last OVA challenge. Antagomir treatments (50 μg/dose of
Ant i.n.) were performed on days 11, 13 and 15, 6 hours before challenges. Dexamethasone
(DEX) treatments (3 mg/kg body weight, i.p.) were performed on day 11 and every second day
thereafter 1 hour before challenges. Intranasal treatments of animals were performed under
light anesthesia with isoflurane (Pharmachem, Australia).
Airway hyper-responsiveness (AHR) measurement
AHR was assessed invasively in mice anesthetised with 100 mg/kg ketamine (Ceva, Australia)
and 10 mg/kg xylazine (Ilium, Australia) by measurement of total lung resistance and dynamic
compliance using a FinepointTM series Resistance and Compliance system (Buxco, North
Carolina USA) [22]. Percentage increase over baseline (PBS) in response to increasing doses of
nebulized methacholine was calculated.
Collection and analysis of bronchoalveolar lavage (BAL) fluid
The left lobe of the lung was tied off, leaving the right lung open for BAL fluid collection. BAL
samples were collected in Hanks Buffered Saline Solution (HBSS) (Gibco, Invitrogen) using a
cannula inserted into the trachea. For differential cell counts, BAL samples were prepared by
centrifugation, red blood cell lysis in hypotonic solution, counted on a hematocytometer and
cytospun onto glass slides (Shandon-4). Cytospin slide preparations were stained with May
Grünwald and Giemsa stain according to manufacturer’s instructions (ACR, Australian Scien-
tific). Slides were analysed by light microscopy and differential cell counts performed based on
cell morphology (minimum of 300 cells per slide).
Lung histology
A transverse section of the left lung lobe was prepared and fixed in 10% neutral buffered forma-
lin and processed for histology (John Curtin School of Medical Research, Australian National
University, Canberra, ACT, Australia). Fixed tissue was embedded in paraffin and sections
were stained with either hematoxylin and eosin (for eosinophil quantification) or Periodic
acid-Schiff (for mucous secreting cell quantification). Sections were examined by light micros-
copy. Cell counts were performed and averaged to give a result in cells/100 μm.
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RNA extraction
Total RNA samples were purified from lung tissue (either whole lung or blunt dissected airway
and parenchyma) for miRNA profiling and gene and miRNA expression analysis. Lung tissue
was placed in RNALater (Invitrogen, Carlsbad, CA) and stored at -80˚C. Total RNA was iso-
lated by phenol-chloroform separation and isopropanol precipitation, quantified on a Nano-
drop 1000 spectrophotometer (Thermo Scientific, USA) and assessed using an 2100
Bioanalyzer Instrument (Agilent Technologies, USA). Samples with a RNA integrity number
(RIN) below 8 were excluded from further analysis.
MiRNAmicroarrays
MiRNAmicroarrays were performed according to manufacturer’s protocol using the miRNA
Complete Labeling and Hyb Kit and Mouse miRNAMicroarray Release 12.0 slides (Agilent
Technologies, Technology number 21828, version 2010.11.04). Samples were hybridized,
washed and scanned with a High-Resolution C Scanner (Agilent Technologies, USA). Data
was processed using the Feature Extraction software version 10.7.3.1 and data analysis was per-
formed using Genespring GX version 11.5.1 (Agilent Technologies, USA). The miRNA micro-
array data has been made publicly available at NCBI (GEO accession number GSE72793).
Quantitative PCR
For gene expression analysis, qPCR was performed using random hexamer primers (Invitro-
gen) and Superscript III (Invitrogen), on a T100 thermal cycler (Bio-Rad, Hercules, CA). Rela-
tive qPCR quantification was performed on a Mastercycler1 ep realplex system (Eppendorf,
Australia), using SYBR reagents. Primer sets (Table 1) were designed to specifially amplify
mRNA products and results normalized to the house-keeping gene HPRT. For the detection of
pri-mir-155, a specific primer set (Mm03306395_pri) and TaqMan1 Universal PCR Master
Mix No AmpErase UNG (both Life Technologies) was used for qPCR quantification.
For miRNA expression analysis, miRNA-specific cDNA was generated using a TaqMan1
MicroRNA Reverse Transcription Kit and gene-specific primers (mmu-miR-18a-5p (ID
002422), mmu-miR-21a-5p (ID 000397), mmu-miR-144-3p (ID 002676), mmu-miR-155-5p
(ID 002571), mmu-miR-155-3 (464539_mat), mmu-miR-188-5p (ID 002320), mmu-miR-
223-3p (ID 002295), mmu-miR-449a-5p (ID 001030), mmu-miR-451a (ID 001141) and
snoRNA202 (ID 001232); Life Technologies). qPCR was then performed on a Mastercycler1
Table 1. Primer sequences used for qPCR analysis (indicated in 5’-3’ orientation).
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ep realplex system (Eppendorf, Australia) using TaqMan1 Universal PCRMaster Mix No
AmpErase UNG and normalized to the house-keeping RNA sno202.
Antagomirs (Ant)
Target miRNA sequences from miRBase (Wellcome Trust, Sanger Institute, Cambridge,
United Kingdom) were used to design specific antisense Ant. Ant-155 (5'mA..mC..mC.mC.
mC.mU.mA.mU.mC.mA.mC.mA.mA.mU.mU.mA.mG.mC.mA.mU..mU..mA..mA.. 3'-
Chol) and a scrambled control (Scramble; 5'mU..mC..mA.mC.mA.mA.mC.mC.mU.mC.mC.
mU.mA.mG.mA.mA.mA.mG.mA..mG..mU..mA..3'-Chol) were synthesized by Dharma-
con Inc (Lafayette, Colorado), where m denotes 2’-O-Methyl-modified phosphoramidites, 
denotes phosphorothioate linkages, and -Chol denotes hydroxyprolinol-linked cholesterol.
Fluorescently labeled Ant containing a 5’-DY547 phosphoramidite modification was used
where indicated.
T cell culture
CD4+ T cells were purified from spleen tissue by magnetic cell separation using murine CD4
(L3T4) microbeads according to manufacturer’s protocol (Miltenyi Biotec, Germany). CD4+ T
cells were then stained with fluorescently labeled antibodies against CD4, CD44, CD62L and
CD25 and sorted on a FACSAria cell sorter (BD Pharmingen, USA) to purify naïve T cells
(CD4+CD44loCD62LhiCD25-; clones RM4-5; IM7, MEL-14, PC61; BD Pharmingen, USA). For
proliferation assays, CD4+ T cells were labeled with carboxyfluorescein diacetate succinimidyl
ester (CFSE) as previously described [23]. For the activation of Th cells, purified CD4+ T cells
were stimulated in complete media (DMEM, 10% FCS, 2 mM L-glutamine, 50 μM β-mercap-
toethanol, 100U/ml Penicillin-Streptomycin; Invitrogen, Australia) with plate-bound anti-
CD3ε (1 μg/ml; Clone 145-2C11; BD Pharmingen, USA) and soluble anti-CD28 (2 μg/ml;
Clone 37.51; BD Pharmingen, USA) for 3 days.
Flow cytometry
Lung tissue was digested in HEPES buffer containing collagenase D (Sigma-Aldrich, St. Louis,
MO) and DNAse, then forced through a 70-μm strainer. Spleen samples were forced through
70-μm strainers without enzymatic digestion. After isolation, red blood cell lysis was performed
using ammonium chloride solution. For in vitro Ant uptake assays, CD4+ T cells were sepa-
rated with magnetic beads and both CD4+ and CD4- cell preparations were incubated with
fluorescent Ant for 1 h at the indicated concentrations. For flow cytometry staining, all cells
were treated with Fc block before staining with fluorochrome-conjugated Abs. For flow cytom-
etry analysis, labeled cell samples were fixed overnight in PBS containing 2% FCS and 0.1%
paraformaldehyde, collected on a BD FACSCanto II flow cytometer and analyzed using FACS-
Diva software (BD Biosciences). For fluorescence-activated cell sorting, fluorochrome-labeled
cell preparations were separated on a FACSAria III cell sorter (BD Pharmingen, USA) based
on surface marker expression, as indicated. The purity of sorted cells was confirmed as>99%.
The following antibodies were used (BD Biosciences): B220 (RA3-6B2), CD3e (145-2C11),
CD4 (RM4-5), CD8a (56–6.7), CD11b (M1/70), CD11c (N418), CD45 (30-F11), Epcam
(G8.8), F4/80 (BM8), Ly6G (1A8), SiglecF (E50-2440).
Statistical analysis
P values were calculated using the unpaired Mann-Whitney test. P values< 0.05 were consid-
ered statistically significant.
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Results
MiRNA profiling identifies differential miRNA expression in AAD lung
To assess the role of miRNAs in AAD, we utilised a steroid-sensitive, OVA-driven mouse
model (see S1 Fig for characterisation of inflammation and morphological changes). We per-
formed microarray analysis of miRNA expression in whole lung samples from PBS-sensitised/
challenged mice (PBS/PBS), PBS-sensitised/OVA-challenged mice (PBS/OVA), OVA-sensi-
tised/challenged mice (OVA/OVA) and OVA-sensitised/challenged mice treated with dexa-
methasone (OVA/OVA DEX). 228 of the total 611 arrayed miRNAs were detected in mouse
lungs in at least one experimental group (Fig 1A). Of the 228 expressed miRNAs, 29 miRNAs
Fig 1. MiRNA profiling identifies differential miRNA expression in lungs of allergic mice. Expression of 611 miRNAs was investigated in whole lung
samples by microarray. 228 miRNAs were detected in the lungs, with 29 altered between experimental groups (A). Venn diagram of statistically-significant
differentially expressed miRNAs (fold-change2) between PBS/PBS (PBS) and OVA/OVA, PBS/PBS and OVA/OVA DEX (DEX) and OVA/OVA and OVA/
OVA DEX (B). Hierarchical cluster analysis of treatment conditions based on differentially expressed miRNAs. Heat-map representation of normalised
expression levels for differentially expressed miRNAs. The boxes in colour indicate the normalised intensities of miRNA expression, with blue indicating low
and red indicating high expression (C). qPCR detection of 6 altered miRNAs (D) and two DEX-responsive miRNAs (E). Expression is normalised relative to
control RNA sno202. Fold changes for selected miRNAs is graphed for both microarray and qPCR analysis (OVA/OVA versus PBS/PBS) (F). Error bars
represent SEM (n = 6 animals/group). Mann-Whitney test was used to compare two groups with another. P values of less than 0.05 are indicated by * and
less than 0.01 by ** and less than 0.001 by ***.
doi:10.1371/journal.pone.0144810.g001
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exhibited significant differences in expression between one or more groups (Fig 1A–1C,
Table 2).
Only one miRNA (mmu-miR-135b-5p) was detected with>2-fold change in the PBS/PBS
compared to PBS/OVA group. Four miRNAs were altered>2-fold in the OVA/OVA DEX-
treated group compared to PBS/PBS (mmu-miR-551b-3p increased and mmu-miR-188-5p,
-449a-5p and -503-5p decreased). The majority of altered miRNAs (22 of 29) were upregulated
(compared to 7 downregulated miRNAs) in the OVA/OVA allergic group compared to PBS/
PBS, PBS/OVA and OVA/OVA DEX (Fig 1C, Table 1). Hierarchical clustering of the differen-
tially expressed miRNAs demonstrated the most similarity between PBS/PBS and PBS/OVA,
followed by OVA/OVA DEX (Fig 1C). The OVA/OVA group exhibited the largest differences
when compared to the other experimental groups. Interestingly, most of the differentially regu-
lated miRNAs (26 of 29) were steroid-sensitive, demonstrating alterations after DEX treatment
(Fig 1B and 1C).
To verify our microarray results, we selected 8 (from the 29 altered) miRNAs and performed
qPCR. The 8 miRNAs were selected based on their expression pattern, expression level and
Table 2. Differentially expressedmiRNAs in whole lung. Systematic name and fold changes for the different treatment groups are given for 29 miRNAs.
Fold changes over 2 are highlighted in bold.






FC OVA/OVA vs OVA/
OVA DEX
FC OVA/OVA DEX vs
PBS/PBS
mmu-let-7d-3p 1.32 -1.38 -1.82 -2.60 1.89
mmu-miR-1224-5p -1.02 2.48 2.54 2.40 1.04
mmu-miR-130b-3p 1.00 2.22 2.21 2.87 -1.30
mmu-miR-135a-1-3p 1.43 3.40 2.37 5.12 -1.51
mmu-miR-135b-5p 3.53 4.86 1.38 4.51 1.08
mmu-miR-139-3p 1.38 3.25 2.36 2.81 1.16
mmu-miR-142-3p -1.02 1.90 1.93 2.01 -1.06
mmu-miR-144-3p 1.10 -1.47 -1.61 -2.23 1.52
mmu-miR-155-5p 1.01 4.04 4.00 6.66 -1.65
mmu-miR-188-5p -1.96 3.63 3.12 3.51 -2.99
mmu-miR-1897-5p 1.19 3.12 2.62 2.58 1.21
mmu-miR-18a-5p 1.05 2.33 2.21 2.39 -1.03
mmu-miR-193b-3p -1.35 -2.29 -1.70 -1.87 -1.22
mmu-miR-21a-5p 1.29 2.77 2.15 2.64 1.05
mmu-miR-223-3p 1.08 2.30 2.12 1.30 1.76
mmu-miR-328-3p 1.13 -1.58 -1.78 -2.56 1.62
mmu-miR-362-5p 1.07 2.95 2.77 2.40 1.23
mmu-miR-378a-3p -1.13 2.21 2.50 2.29 -1.03
mmu-miR-378a-5p -1.16 1.52 1.76 2.19 -1.45
mmu-miR-449a-5p 1.20 2.02 1.68 4.19 -2.08
mmu-miR-451a 1.05 -1.59 -1.68 -2.36 1.48
mmu-miR-486-5p 1.01 -1.62 -1.64 -2.44 1.51
mmu-miR-503-5p -1.14 1.06 1.21 2.62 -2.47
mmu-miR-532-5p 1.02 2.05 2.02 1.94 1.06
mmu-miR-551b-3p 1.34 -1.72 -2.30 -3.74 2.18
mmu-miR-680 1.03 6.24 6.24 6.24 -1.30
mmu-miR-721 1.54 6.31 4.61 6.31 1.70
mmu-miR-7a-5p 1.08 2.12 1.97 2.09 1.01
mmu-miR-877-5p -1.19 5.14 5.14 5.14 -1.42
doi:10.1371/journal.pone.0144810.t002
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existing evidence for a role in inflammatory disease (Fig 1D and 1E). Six of the miRNAs
assessed (mmu-miR-18a-5p, -21a-5p, -155-5p, 188-5p, -223-3p and -449a-5p) were signifi-
cantly increased following OVA sensitization and challenge (Fig 1D). All 6 of these miRNAs
decreased following DEX treatment, demonstrating steroid-sensitivity (Fig 1D). Two of the
assessed miRNAs (mmu-miR-144-3p and -451a) were increased in response to DEX treatment
(Fig 1E). We also assessed the expression levels of two miRNAs previously associated with lung
disease (mmu-miR-146a-5p and mmu-miR-221) [24, 25], but could not detect differential
expression in this study (data not shown). Importantly, qPCR-validated expression profiles
closely matched our array data, confirming the validity of the observed alterations (Fig 1F).
Taken together, we could successfully determine the lung miRNA expression profile and iden-
tify AAD-associated miRNA expression changes in the lung.
Identification of novel predicted targets of altered miRNAs
To identify potential mRNA targets of the differentially regulated miRNAs, we used miRSys-
tem, an integrated database for target gene prediction [26]. For the 29 differentially expressed
miRNAs identified in our model, an average of 198 target genes was predicted for each individ-
ual miRNA. However, in silicomiRNA target prediction results in high numbers of false-posi-
tives [27]. As multiple miRNA binding sites can cooperatively mediate post-transcriptional
regulation of target gene expression [28], we hypothesized that genes targeted by multiple dif-
ferentially expressed miRNAs are most likely to be genuine targets. To investigate this possibil-
ity, we used miRSystem to assess overlapping target genes predicted to be regulated by multiple
members of the 29 differentially expressed miRNAs.
Over 40% of the computated target genes (based on miRSystem) had predicted miRNA-
binding sites for more than 1 of the 29 differentially regulated miRNAs, while ~20% had 3 or
more predicted miRNA binding sites. A small number (44 target genes, representing just over
1% of all computated targets), had 6 or more predicted miRNA binding sites for the differen-
tially expressed miRNAs (Fig 2A, Table 3). On average, the 44 candidate genes were targeted
by 7 differentially expressed miRNAs each, of which 6 were upregulated and 1 was downregu-
lated (Table 3).
To determine whether our in silico approach predicted real changes in target mRNA expres-
sion levels, we characterised selected target genes in airway wall and parenchyma samples (Fig
2B and 2C). ACVR2A, MIER3, PTEN and TNRC6B have the highest number of putative bind-
ing sites for upregulated miRNAs (7 to 9) and ACVR2A, MIER3 and TNRC6B have the highest
difference between up- and downregulated miRNAs (up to 8). The remaining 4 target genes
were assessed based on previous literature: ATXN1 has been associated with asthma [29],
NFAT5 is implicated in the regulation of proinflammatory cytokines [30], NR3C1 is a target
for steroid-based asthma treatments [31] and TAB2 is a validated miR-155-5p target [32]. All 8
of the tested target genes were significantly downregulated in the OVA/OVA group in both air-
way wall and parenchyma and this difference was again sensitive to DEX treatment (Fig 2C).
Taken together, our bioinformatic analysis identified novel asthma-associated genes that may
be regulated by a network of differentially expressed miRNAs.
Mir-155 is induced in allergic lung tissues and immune cells
As miR-155-5p was the most differentially upregulated miRNA identified in our study (~5
fold-change in OVA/OVA versus control groups) and was reduced to baseline following ste-
roid treatment, we chose miR-155-5p for further analysis. We detected increased levels of both
pri-mir-155 and miR-155-3p transcripts in OVA/OVA mice (Fig 3A). The absolute expression
level of miR-155-3p was much lower than miR-155-5p (Figs 1D and 3A). While miR-155-3p
MiRNA Profiling and Targeting of miR-155 in Allergic Airways Disease
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Fig 2. Predicted targets of alteredmiRNAs. Predicted target genes for the 29 differentially expressed miRNAs (based on miRSystem analysis) plotted
against the number of predicted miRNA binding sites (A). Number of differentially expressed targeting miRNAs for 8 predicted target genes (change in OVA/
OVA versus PBS/PBS) (B). qPCR assessment of 8 putative target genes in airway wall and parenchyma (C). Expression data is normalised relative to
control HPRT. Error bars represent SEM (n = 6 animals/group). Mann-Whitney test was used to compare two groups with another. P values of less than 0.05
are indicated by *, less than 0.01 by **, less than 0.001 by *** and less than 0.0001 by ****.
doi:10.1371/journal.pone.0144810.g002
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Table 3. Predicted target genes with multiple target sites. Genes with target sites for 6 or more of the 29 identified differentially regulated miRNAs. The
number of targeting miRNAs that are upregulated and downregulated are shown as well as the difference.
Target
gene







PTEN phosphatase and tensin homolog 12 8 4 +4
TNRC6B trinucleotide repeat containing 6b 10 9 1 +8
CPEB3 cytoplasmic polyadenylation element binding
protein 3
9 7 2 +5
TBL1XR1 transducin (beta)-like 1X-linked receptor 1 9 7 2 +5
AAK1 AP2 associated kinase 1 9 8 1 +7
SYNCRIP synaptotagmin binding, cytoplasmic RNA
interacting protein
8 7 1 +6
ACSL4 acyl-CoA synthetase long-chain family member 4 8 7 1 +6
CSNK1G1 casein kinase 1, gamma 1 8 7 1 +6
SERTAD2 SERTA domain containing 2 8 7 1 +6
ZFP148 zinc finger protein 148 7 5 2 +3
ATXN1 ataxin 1 7 6 1 +5
BCL2L2 BCL2-like 2 7 5 2 +3
ZFP704 zinc finger protein 704 7 5 2 +3
MBNL1 muscleblind-like 1 (Drosophila) 7 6 1 +5
TMEM55B transmembrane protein 55b 7 7 0 +7
ELAVL2 ELAV (embryonic lethal, abnormal vision,
Drosophila)-like 2
7 4 3 +1
RICTOR RPTOR independent companion of MTOR,
complex 2
7 7 0 +7
ACVR2A activin receptor IIA 7 7 0 +7
NUFIP2 nuclear fragile X mental retardation protein
interacting protein 2
7 6 1 +5
MIER3 mesoderm induction early response 1, family
member 3
7 7 0 +7
MECP2 methyl CpG binding protein 2 7 6 1 +5
ZCCHC14 zinc finger, CCHC domain containing 14 6 6 0 +6
AFF4 AF4/FMR2 family, member 4 6 4 2 +2
TGFBR1 transforming growth factor, beta receptor I 6 5 1 +4
DCX doublecortin 6 5 1 +4
CAMTA1 calmodulin binding transcription activator 1 6 4 2 +2
TCF4 transcription factor 4 6 4 2 +2
FBXO28 F-box protein 28 6 5 1 +4
SMG1 SMG1 homolog, phosphatidylinositol 3-kinase-
related kinase
6 6 0 +6
RBM33 RNA binding motif protein 33 6 4 2 +2
FUBP1 far upstream element (FUSE) binding protein 1 6 6 0 +6
QK quaking 6 5 1 +4
UBE2D3 ubiquitin-conjugating enzyme E2D 3 (UBC4/5
homolog, yeast)
6 5 1 +4
GSK3B glycogen synthase kinase 3 beta 6 5 1 +4
PHF17 PHD finger protein 17 6 5 1 +4
IGF1R insulin-like growth factor I receptor 6 4 2 +2
SOX6 SRY-box containing gene 6 6 5 1 +4
NR3C1 nuclear receptor subfamily 3, group C, member 1 6 3 3 0
NFAT5 nuclear factor of activated T-cells 5 6 5 1 +4
(Continued)
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NF1 neurofibromatosis 1 6 5 1 +4
NAA50 N(alpha)-acetyltransferase 50, NatE catalytic
subunit
6 6 0 +6
MLL1 myeloid/lymphoid or mixed-lineage leukemia 1 6 4 2 +2
SOX11 SRY-box containing gene 11 6 4 2 +2
TRIM2 tripartite motif-containing 2 6 5 1 +4
Average 7 6 1 +4
doi:10.1371/journal.pone.0144810.t003
Fig 3. Mir-155 expression profiles in allergic lung tissues and isolated immune cells. qPCR assessment of expression levels for primary mir-155 and
mature miR-155-3p in whole lungs from PBS/PBS, OVA/OVA and OVA/OVA DEX-treated mice (A). miR-155-5p expression levels assessed in the airway
wall and parenchyma of PBS/PBS and OVA/OVAmice (B). miR-155-5p expression in spleen, PBLNs, total lung cells and FACS-sorted lung cell subsets (C).
Th cells, B cells, epithelial cells, neutrophils, Ly6G-CD11b+ cells (predominantly DCs, macrophages and monocytes), alveolar macrophages (Macs) and
eosinophils. See Table 4 for surface marker expression on the sorted cell populations. Expression data is normalised relative to sno202 for mature miRNAs
and HPRT for primary mir-155. Error bars represent SEM for A and B (n = 8 animals/group). Mann-Whitney test was used to compare two groups with
another. P values of less than 0.05 are indicated by * and less than 0.01 by ** and less than 0.001 by ***.
doi:10.1371/journal.pone.0144810.g003
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We also performed experiments to assess which cell types express miR-155-5p in our
model. In isolated airway wall and parenchymal tissue samples, similar expression levels of miR-
155-5p were detected with significant increases in OVA/OVAmice (Fig 3B). There was no
detectable change in miR-155-5p expression in the spleen or PBLN, although increased expres-
sion was confirmed in total lung cells (Fig 3C). In sorted lung cell populations (sorting strategy
indicated in Table 4), increased miR-155-5p expression was detected in Th cells, Ly6G-CD11b+
cells (predominantly dendritic cell, macrophage and monocyte populations), and alveolar macro-
phages fromOVA/OVAmice, compared to controls (Fig 3C). High miR-155-5p expression was
also detected in eosinophils, with low expression observed in sorted epithelial cells and neutro-
phils (Fig 3C). These results clearly show that miR-155-5p is expressed by most haematopoietic
cells in the lung and is upregulated in the context of allergic inflammation.
In vivo antagomir-based targeting of miR-155-5p decreases expression,
but has no impact on AAD severity
MiR-155-5p is highly upregulated in OVA/OVA mice, highly expressed in infiltrating immune
cell populations and has previously been shown to play key roles in inflammation [6, 33–35].
We therefore sought to assess its function in vivo using an antagomir (Ant-155). Intranasal
administration of Ant-155 significantly reduced miR-155-5p levels both in airway wall and
parenchymal tissue samples (Fig 4A), with no effect on miR-155-3p or pri-mir-155 (Fig 4B),
compared to scrambled antagomir (Scramble)-treated controls. Antagomir administration
reduced miR-155-5p levels to the levels detected in PBS/OVA animals.
Having established that intranasal Ant-155 treatment effectively reduced miR-155-5p levels
in vivo, we examined the effect of Ant treatment on hallmark features of AAD. Ant-155 had no
significant effect on immune cell infiltration into the broncho-alveolar space following allergen
challenge (Fig 4C and 4D) or the development of methacholine-induced AHR (Fig 4E and
Figure A in S2 Fig). While Ant treatment alone (Scramble versus OVA/OVA control) showed
a tendency towards increased BALF neutrophils, there were no changes in neutrophil numbers
following specific Ant-155 treatment (Ant-155 versus Scramble) (Fig 4C). Ant-155 treatment
also had no effect on gene expression for key genes induced in our AADmodel (IL-5, IL-13
and Muc5ac; Figure B in S2 Fig). Ant-155 treatment did have a small impact on expression of
two predicted target genes (ACVR2A and TAB2; Figure C in S2 Fig). Taken together, we show
effective and specific inhibition of miR-155-5p following intranasal antagomir administration,
but failed to detect any discernible effect on AAD severity.
Table 4. Sorting strategy for different cell populations. Sorted cell populations were gated based on FSC (forward scatter), SSC (side scatter) and sur-
face marker expression characteristics.
Identifier Th cells B cells Epithelial cells Neutrophils Ly6G-CD11b+ cells Alveolar Macs Eosinophils
FSC low low low Int high low
SSC low low Int low high high
CD45 + + - + + + +
B220 - + Int - - -
CD4 + - - - - -
CD8 - - - - Int -
CD11b - - + + + +
CD11c - - Int Int + -
Epcam +
Ly6G - - + - Int Int
SiglecF - - - - + +
doi:10.1371/journal.pone.0144810.t004
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Antagomir uptake differs across immune cell populations in vitro and in
vivo
Recent literature using mir-155-/- mice suggests a functional role for miR-155-5p in AAD, in
particular CD4 T cells [18, 19]. Based on these findings, it was surprising that we failed to
Fig 4. In vivo targeting of miR-155-5p with an antagomir effectively decreases expression but has no impact on disease. Expression of miR-155-5p
in airway wall and parenchymal tissue samples of OVA/OVAmice treated with non-specific Scramble or miR-155-5p-specific Ant-155 (A). Primary mir-155
and mature miRNAmiR-155-3p, in whole lungs of OVA/OVAmice treated with non-specific Scramble or miR-155-5p-specific Ant-155 (B). Expression data is
normalised relative to sno202 for mature miRNAs and HPRT for primary mir-155. Eosinophil (Eos), neutrophil (Neu), lymphocyte (Lym) and macrophage
(Mac) (C) and total cell numbers (D) in BALF from OVA/OVAmice treated with non-specific Scramble or Ant-155. Total lung resistance and dynamic
compliance in response to 5 mg/ml inhaled methacholine in OVA/OVAmice treated with non-specific Scramble or Ant-155, presented as percentage change
over baseline (saline) (E). Error bars represent SEM (n = 8 animals/group). Mann-Whitney test was used to compare two groups with another. P values of
less than 0.05 are indicated by *, less than 0.01 by ** and less than 0.0001 by ****.
doi:10.1371/journal.pone.0144810.g004
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detect a phenotype in our model, despite specific inhibition of miR-155-5p. To better under-
stand our differing results, weassessed whether Ant uptake is altered across lung cell subsets
using a fluorescent antagomir. Granulocytes (SSChi) exhibited high levels of uptake across all
Ant concentrations in vitro, with nearly 100% of cells positive at 0.25 μMAnt (Fig 5A). In con-
trast, B220+ and CD4+ cells, exhibited lower uptake at comparable concentrations (Fig 5A).
For B220+ cells, 1 μMAnt was required to obtain>75% positive fluorescence (Fig 5A). For
CD4+ cells, 2 μM fluorescent Ant were necessary to obtain>80% positively-labeled cells (Fig
5A). Even at concentrations of 4 μMAnt, CD4+ cells exhibited lower antagomir uptake (based
on MFI) than granulocytes treated with 0.25 μMAnt (Fig 5A). At the high doses of Ant
required for CD4+ cell uptake (5 μM), we noticed significant impacts on cell viability and pro-
liferation. Exposure to either non-specific Scramble or miRNA-specific Ant-155 significantly
reduced CD4+ T cell proliferation, with a clear reduction in the numbers of CD4+ T cells that
have divided 4 or more times in a CFSE-based proliferation assay (Fig 5B). This effect was also
observed with other sequence-specific Ant (data not shown). Taken together, these results
demonstrate that effective antagomir uptake is both dose- and cell type-dependent. While mye-
loid cells can be targeted effectively at low doses, targeting of lymphocytes (CD4+ T cells and
B220+ B cells) is less efficient and effective uptake requires high concentrations that induce tox-
icity and inhibit cell proliferation.
To determine whether similar differences in uptake occur in vivo, we also administered fluo-
rescently-labeled Ant intranasally to either control or OVA-sensitized/challenged mice. Similar
to our findings in vitro, Ant fluorescence levels were high in CD11c+, F4/80+ and Ly6G+ popu-
lations (representative of DCs, macrophages and neutrophils, respectively) (Fig 5C). However,
MFI was particularly low across all lymphocyte populations (B220+ and CD4+ representative
for B cells and T cells) and CD4+ cells in particular exhibited low percentages of fluorescent
Ant-positive cells (Fig 5C). No fluorescence was detected in spleen immune cells, suggesting
that intranasal administration of Ant remains limited to the lung (Fig 5C).
We have also assessed the uptake of fluorescent Ant in blood, liver and lung immune cells
following intranasal administration in naïve mice. A single dose of 50 μg Ant resulted in lower
uptake in blood and liver immune cells compared to the lung, both in terms of percentage of
stained cells as well as fluorescent intensity (Figures A and B in S3 Fig). Similarly to the lung,
we again observed lower percentages of fluorescent Ant-positive lymphocytes in the blood and
liver. Noticeably, lung epithelial cells (CD45-Epcam+) also show good uptake of Ant (Figures C
and D in S3 Fig). Taken together, we show that intranasal Ant delivery effectively targets mye-
loid and dendritic cell populations in the lung, but has limited ability to target lung lympho-
cytes and remains largely restricted to cells within the lung.
Discussion
Current knowledge on the role of miRNAs in asthma pathogenesis remains limited. One previ-
ous study has used an acute OVA-induced model of AAD (aerosol delivery and challenge over
a 7-day timecourse), but failed to identify alterations in miRNAs previously identified in other
mouse models of AAD (including let-7b, miR-21 or miR-145) [36]. Our assessment identified
29 differentially expressed miRNAs, approximately 13% of all expressed miRNAs (228 total),
comparable to the percentage of altered genes found in previous mRNA profiling studies [37–
39]. The majority of the altered miRNAs (22 of 29) were increased in disease, suggesting a gen-
eral upregulation of miRNA expression in our model of AAD.
Most of the differentially expressed miRNAs identified (26 of 29) were sensitive to DEX
treatment. This is similar to data from asthmatic patient samples where the majority of differ-
entially expressed miRNAs in airway epithelial cells are at least partially restored upon steroid
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treatment [9]. Steroids have an anti-inflammatory effect and may regulate miRNA expression
in the lung either directly or indirectly (e.g. by decreasing lung inflammation and immune cell
infiltration). The latter is particularly relevant for miRNAs expressed at high levels in inflam-
matory cells, such as miR-155-5p [40].
Interestingly, 5 of the 29 differentially expressed miRNAs identified in our study (let-7d-3p,
miR-18a-5p, -21a-5p, -155-5p and -223-3p) have previously been implicated in inflammatory
diseases [6, 14, 15, 18, 33, 41–45]. Furthermore, there is evidence for a contribution of let-7,
mir-21 and mir-155 in AAD [12–15, 17–19]. Conflicting results have been reported for the
role of let-7 in AAD, which may be explained by varying approaches employed to target let-7
expression (e.g. let-7 family inhibitor vs. let-7 mimic vs. let-7b specific inhibitor) as well as dif-
ferences in the studied models (e.g. OVA vs. HDM) [14, 15, 17].
Based on the identified differentially expressed miRNAs, we performed computational pre-
dictions of miRNA-gene interactions to identify potential downstream targets. To limit predic-
tion variability, we used miRSystem, which requires at least three different algorithms to
predict the same miRNA-target gene interaction and importantly, also includes experimentally
verified targets [26]. To provide further stringency, we focused on genes predicted to be tar-
geted by more than one of the differentially expressed miRNAs. This approach identified 44
genes that were predicted to be targeted by at least 6 of the 29 identified miRNAs.
From the list of 44 predicted target genes, we analysed the expression of 8 genes (ACVR2A,
ATXN1, MIER3, NFAT5, NR3C1, PTEN, TAB2 and TNRC6B). As predicted, all 8 target genes
were significantly downregulated in OVA/OVAmice. Importantly, our analysis demonstrated
changes in all tested targets, contrary to the high false-positive rates that typically occur using
in silico target prediction [27]. To date, in silico target prediction rarely accounts for multiple
miRNA binding sites in predicted target genes, despite evidence suggesting that multiple
miRNA binding sites per target gene are common and the potential for synergistic regulation
of miRNA target genes [46–50]. As such, we suggest that using combinatorial in silico target
prediction may be useful at identifying true targets in other miRNA profiling studies.
Three of the predicted target genes, namely ATXN1, NR3C1 and PTEN, have previously
been associated with asthma [29, 31, 51–57]. ATXN1 regulates extracellular matrix remodeling
and lung alveolarization [29]. ATXN1 was significantly reduced in OVA/OVA mice, suggest-
ing that miRNA-mediated inhibition of ATXN1 may contribute to remodeling in this model of
AAD. NR3C1, also known as glucocorticoid receptor (GR), binds to GR-response elements
(GRE) and activates transcription of GRE-controlled genes [31, 58]. GR translocation sup-
presses inflammatory gene expression and glucocorticoids are a main-stay treatment in severe
asthmatic disease [31]. Of the 6 differentially regulated miRNA predicted to target NR3C1, two
(miR-18a and miR-142-3p) have previously been shown to target NR3C1 directly [59–63].
While PTEN is best characterised as a cancer-related gene, it is also proposed to regulate of
asthma pathogenesis [54–57, 64, 65]. PTEN protein levels are reduced in the lungs of allergen
challenged mice, which correlates with increased PI3K activity [55].
The remaining predicted target genes (ACVR2A, MIER3, NFAT5, TAB2 and TNRC6B) are
poorly studied. ACVR2A is a receptor kinase in the activin signaling pathway that regulates
proliferation and is directly targeted by miR-29b and miR-181a [66–68]. MIER3 is a protein
Fig 5. Antagomir efficiency varies across immune cell populations. Isolated lung cells were incubated with fluorescently (DY547)-labeled Ant at
indicated concentrations for 1 hour. Mean fluorescent intensity and percentage of DY547+ cells for granulocytes (SSChi), B220+ and CD4+ cells (A). CD4+ T
cells were CFSE-labeled and cultured with 5 μMAnt for 3 days. Representative histogram plots and proliferation analysis for unlabeled and unstimulated,
CFSE-labeled controls (Controls), PBS-treated (PBS) and Ant-treated (either Scramble or Ant-155) CD4+ T cells (B). Representative graphs from 3
independent experiments. Error bars SEM (n = 3 replicates/group). Fluorescently-labeled Ant uptake by lung immune cells in vivo following intranasal Ant
administration (C). Mean fluorescent intensity and percentage of DY547+ cells for CD11c+, F4/80+, Ly6G+, B220+ and CD4+ cell populations.
doi:10.1371/journal.pone.0144810.g005
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with no known function. NFAT5 is a member of the NFAT/Rel family of transcription factors [69]
that regulates the production of proinflammatory cytokines [30]. TAB2 is targeted by miR-23b
and miR-155 [32, 70] and while no role for TAB2 has been identified in asthma, it is an adaptor in
the TLR/IL-1 signaling cascade and may regulate inflammation in asthma [32]. TNRC6B associ-
ates with Argonaute proteins and promotes miRNA target gene regulation [71–73]. The finding
that TNRC6Bmay also be regulated by miRNAs, suggests a potential feedback loop whereby
altered miRNA expression may impact on miRNA-mediated regulation processes in AAD.
Our findings provide novel insight into the complex regulatory networks underlying AAD
and identify several differentially expressed target genes not previously associated with asthma,
which may provide insights into disease mechanisms. More broadly, our findings highlight the
impact of multiple altered miRNAs on individual genes and the utility of considering overlap-
ping miRNA expression to better identify targets. It remains to be determined experimentally
whether our identified target genes are directly targeted by individual miRNAs. Furthermore,
our target prediction is based on samples from whole lung and its interpretation is complicated
due to significant changes to the cellular composition in OVA/OVA lungs. Increased expres-
sion of miR-155-5p in Th cells, DC and macrophage populations as well as high expression in
infiltrating eosinophils in OVA/OVA mice is likely to contribute to the observed increases in
total lung. Similarly, predicted target gene expression may be altered by both altered expression
levels in lung cells as well as the influx of immune cells. Further experiments are necessary to
determine how miRNAs regulate these in silico identified target genes, whether they are direct
miRNA targets and whether they contribute directly to asthma pathogenesis.
MiR-155-5p was the most differentially regulated miRNA identified in our study (~5 fold-
change in OVA/OVA versus control groups), was sensitive to steroid treatment and highly
expressed in infiltrating eosinophils and increased in Th cell, DC and macrophage populations
in the lung. MiR-155-5p is increased in hematopoietic cells following activation of B cells, T
cells, macrophages and DCs [41, 74, 75] and has been implicated in various inflammatory dis-
eases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and atopic
dermatitis [33, 35, 76–78]. MiR-155 is also increased in the nasal mucosa of allergic patients
with asthma [10] and airway smooth muscle cells from asthmatic patients [11]. Recently, mir-
155-/- mice (which lack pri-mir-155, miR-155-5p and miR-155-3p) were shown to have
decreased lung inflammation in models of AAD [18, 19]. However, the protective effect was
not complete and the impact on lung function and lung remodeling was not assessed. The latter
is of interest, as mir-155-/- mice develop spontaneous lung remodeling with age [79]. Based on
these previous studies, we assessed whether mature miR-155-5p plays a role in our model and
whether inhibitor-based treatment could alter disease pathology.
Although the exact mechanism of Ant uptake into cells is unknown, work by Krutzfeldt
et al. has shown that the chemical properties of antagomirs (increased lipophilicity due to a
cholesterol tag at the 3’-end) are responsible for the cellular uptake into cells [80]. Systemic
Ant-mediated targeting of miRNA function in vivo results in effective, specific, long-lasting
silencing in many tissues [80, 81]. We and others have previously established that intranasal
administration of Ant effectively inhibits miRNA function in the lung [16, 17, 20, 82]. Intrana-
sal Ant-155 administration resulted in specific inhibition of miR-155-5p in both the airway
wall and parenchymal tissue samples. This was accompanied by slight increases in two pre-
dicted targets of miR-155-5p (ACVR2A and TAB2) although expression remained below levels
in control animals. Three other predicted targets (MIER3, NFAT5 and TNRC6B) were not
altered following Ant-155 administration. The overall efficacy of Ant-mediated knockdown of
miR-155-5p was incomplete and comparable to levels detected in PBS/OVA animals and had
no discernible therapeutic effect on hallmark features of disease such as AHR, inflammation or
mucus production. Importantly, neither pri-mir-155 nor miR-155-3p expression levels were
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altered following Ant-155 delivery, suggesting highly specific targeting of mature miR-155-5p.
This is different from other studies that have targeted the mir-155 gene using knockout mice or
precursor molecules, which alter 5p and 3p mature miRNAs and the precursor miRNA (pri-
miR-155) systemically [18, 19, 33, 79, 83]. These differences in experimental approach may
explain why we failed to observe any impact of Ant-155 administration on AAD.
Antagomir studies have mainly investigated whole tissue rather than investigating specific
cell types [16, 17, 81, 84–86]. Little is known about the pharmacokinetics and distribution of
Ant uptake following intranasal administration of Ant. In vitro, administered Ant was quickly
internalized by cells but uptake efficiency varied greatly across different cell types. Myeloid
cells (including macrophages and neutrophils) exhibited higher levels of Ant uptake compared
to lymphocytes. Similarly, in vivo, myeloid cells in the lung exhibited high levels of fluorescent
Ant uptake, while lymphocytes, in particular T cells, exhibit poor uptake. This cellular specific-
ity was also observed in the blood and liver. Furthermore, immune cells in the blood and liver
displayed much lower overall Ant uptake compared to lung immune cells, highlighting the tis-
sue-specificity of the intranasal delivery route. We also observed efficient Ant uptake in lung
epithelial cells, which expressed miR-155-5p at very low levels and showed no altered expres-
sion in our AADmodel. This suggests that miR-155-5p in epithelial cells may not play a func-
tional role in AAD. The differential Ant uptake across different lung cell types may explain
why we failed to achieve a complete reduction in miR-155-5p with Ant-155 treatment.
Variability in Ant-mediated cell targeting could also explain the differences between our
study and the partial protection from AAD observed in mir-155-/- mice [18, 19]. Specifically,
this difference may be driven by a functional role for miR-155-5p in lymphocyte function,
which would be altered in mir-155-/- mice, but not following Ant-155 administration. This
hypothesis is supported by many studies showing a role for mir-155 in lymphocyte function
and disease pathogenesis in bacterial and viral infections and lymphocyte-driven diseases such
as EAE and RA in mir-155-/- mice [79, 87–93]. We therefore speculate that the specific target-
ing of miR-155-5p in lymphocytes, in particular T cells may have a positive therapeutic benefit
in the studied model of AAD. Recently, this has been shown to be the case in a HDMmodel of
AAD, where mixed bone-marrow chimeras with mir-155-deficient T cells were partially pro-
tected from developing allergic airway inflammation and directly targeting mir-155 in Th2
cells prevented the development of Th2-mediated AAD [19]. However, the protective effect
was not as pronounced as in mir-155-/- mice, suggesting that other cell types also contribute to
a protected phenotype. Furthermore, Okoye et.al. identified that T cell-intrinsic mir-155 was
required for efficient Th cell recruitment to the lungs in this model of AAD [19]. In agreement
with these findings, Malmhall et.al. also provide evidence for deficient Th2 cell differentiation
and reduced numbers of lung Th cells in mir-155-/- mice subject to a mouse model of AAD
[18]. In contrast to mir-155-/- mice, specific targeting of miR-155-5p in the lung with intranasal
Ant delivery would not be able to prevent the recruitment of Th cells to the lung. Importantly,
the use of mir-155-/- mice does not answer the question whether mir-155 function is required
during sensitization, challenge or both phases of AAD development. Taken together, these
findings suggest that mir-155 function in T cells is largely responsible for the protective pheno-
type that is observed for mir-155-/- mice in models of AAD.
Summary
The current study provides insight into alterations in miRNA expression and their potential
role in the pathogenesis of allergic asthma, using a mouse model of AAD. We successfully char-
acterised the mouse lung miRNAome and identify novel gene changes following allergen chal-
lenge. While targeting of miR-155-5p with a specific antagomir resulted in specific inhibition
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in vivo, it failed to alter the disease phenotype. We propose that this lack of protection may
result from the observed variation in antagomir uptake, with efficient uptake in myeloid cell
populations and poor uptake in lymphocytes. Taken together, this study provides novel insight
into the complex molecular processes underlying allergic asthma and the limitations of target-
ing miRNAs with antagomir-based strategies. The implications of our results also have impor-
tant consequences on the interpretation of study results using Ant-based treatments.
Supporting Information
S1 Fig. Characterisation of the murine model of allergic airways disease. Total lung resis-
tance and dynamic compliance (percentage change over baseline (saline)) in response to
inhaled methacholine in PBS/OVA, OVA/OVA and OVA/OVA DEX-treated mice (A). Total
BALF white blood cell and differential eosinophil (Eos), neutrophil (Neu), lymphocyte (Lym)
and macrophage (Mac) counts (B). Mucus secreting cell (MSC) and eosinophil counts per
100μm high power field in lung tissue sections (C). IL-5, IL-13 and Muc5ac mRNA expression
levels in airway wall and parenchyma by qPCR (D). Expression data normalised to housekeep-
ing HPRT control RNA levels. Error bars represent SEM (n = 6 animals/group). Mann-Whit-
ney test was used to compare two groups with another. P values of less than 0.05 are indicated
by , less than 0.01 by , less than 0.001 by  and less than 0.0001 by .
(TIF)
S2 Fig. Ant-155 administration has no effect on AHR and Th2 or target mRNA expression.
Total lung resistance and dynamic compliance (percentage change over baseline (saline)) in
response to inhaled methacholine in OVA/OVA treated with non-specific Scramble or miR-155-
5p-specific Ant-155 (A). IL-5, IL-13 andMuc5ac mRNA expression levels in airway wall and
parenchyma tissue by qPCR (B). ACVR2A, MIER3, NFAT5, NR3C1, PTEN, TAB2 and TNRC6B
mRNA expression levels in whole lung tissue samples by qPCR (C). Expression data is normalized
to control RNAHPRT. Error bars represent SEM (n = 8 animals/group). Mann-Whitney test was
used to compare two groups with another. P values of less than 0.05 are indicated by .
(TIF)
S3 Fig. Ant uptake in blood, liver and lung. Ant uptake by blood, liver and lung cells follow-
ing in vivo Ant administration. 50 μg of DY547-labeled Ant was administered intranasally and
uptake determined in single cell preparations from blood, liver and lung after 24 h. Percentage
of DY547+ cells of CD4+, B220+ and CD11b+ cell populations is shown (A). Mean fluorescent
intensity of CD4+, B220+ and CD11b+ cell populations is shown (B). Percentage of DY547+ (C)
and mean fluorescent intensity (D) of lung epithelial cells (CD45-Epcam+) in the lung is
shown. Error bars represent SEM (n = 3). Mann-Whitney test was used to compare two groups
with another. P values of less than 0.05 are indicated by .
(TIF)
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